Group 1 - The board of directors of Yanzhou Coal Mining Company Limited held its 17th meeting on May 30, 2025, with all 11 directors present, confirming compliance with legal and regulatory requirements [1] - The board approved the adjustment of the specialized committee members, replacing Mr. Hu Jiadong with Ms. Rui as a committee member, with unanimous support from all directors present [1][4] - The board approved an internal loan of 1 billion yuan from Shandong Energy Group Luxi Mining Co., Ltd. to its subsidiary, Heze Coal Power Co., Ltd., for a term of 3 years at an interest rate of 3.1%, with asset collateral provided [2][3]

Core Points - The document outlines the information disclosure management measures of China Communications Design Consulting Group Co., Ltd. to enhance the quality and level of information disclosure and protect the rights of the company and its investors [1][2]. Group 1: General Principles - The information disclosure obligations apply to the company, its directors, senior management, shareholders, and other relevant parties involved in significant transactions or changes [2][3]. - Information disclosed must be timely, truthful, accurate, complete, and clear, without misleading statements or omissions [3][4]. - The company must ensure that all investors receive the same information simultaneously, with exceptions only as required by law [4][5]. Group 2: Disclosure Content - Regular reports include annual and semi-annual reports, which must be completed and disclosed within specified timeframes [5][6]. - Annual reports must contain essential company information, financial data, stock and bond issuance details, and significant events affecting the company [6][7]. - The company must disclose any risks that could significantly impact its core competitiveness and future development [6][8]. Group 3: Temporary Reports - Temporary reports are required for significant events that could impact the company's stock price, including major lawsuits, asset impairments, or changes in control [9][10]. - The company must disclose any major changes in its operations or financial performance promptly [10][11]. Group 4: Internal Reporting Mechanism - The internal reporting mechanism for significant information includes immediate reporting to the board of directors upon knowledge of major events [16][17]. - The board secretary is responsible for coordinating and organizing the company's information disclosure work [28][29]. Group 5: Responsibilities and Accountability - The board of directors is responsible for overseeing the information disclosure process, and the chairman is the primary responsible person [28][30]. - Any violations of the disclosure regulations may lead to disciplinary actions against responsible individuals, including potential legal consequences [48][49].

证券代码：603773 证券简称：沃格光电 公告编号：2025-041 江西沃格光电集团股份有限公司 关于最近五年被证券监管部门和证券交易所处罚或采取监 管措施情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江西沃格光电集团股份有限公司（以下简称"公司"）拟实施 2025 年度向 特定对象发行 A 股股票项目，现根据相关法律法规要求，就公司最近五年是否 被证券监管部门和证券交易所处罚或采取监管措施的情况披露如下： 一、公司最近五年被证券监管部门和证券交易所处罚情况 经自查，公司最近五年内不存在被证券监管部门和证券交易所处罚的情况。 二、公司最近五年被证券监管部门和交易所采取监管措施及整改情况 于对江西沃格光电股份有限公司和时任董事会秘书万兵予以监管关注的决定》 （上证公监函〔2020〕0051 号） （1）主要问题 公司具备年产 1 亿片的产能。2020 年 1 月 8 日早间、1 月 9 日晚间，公司在 E 互动中回复投资者提问称，"一加手机潜隐式后摄技术-电致变色技术公司全程 参与，主要工艺工程技术由公司研发。 ...

Core Viewpoint - Wuhan Yifei Laser Co., Ltd. received a warning letter from the Hubei Securities Regulatory Bureau due to significant discrepancies in its financial disclosures, particularly in its annual report and performance announcement [1][2]. Group 1: Violation Details - The company reported a net profit attributable to shareholders of 24.32 million yuan, a decrease compared to the previous year's net profit of 45.315 million yuan [1]. - The company corrected its 2024 annual report, revealing an operating income of 692.0687 million yuan, a net profit of 24.32 million yuan, and a net profit of 9.4123 million yuan after deducting non-recurring gains and losses [1]. Group 2: Regulatory Actions - The company's actions violated the "Administrative Measures for Information Disclosure of Listed Companies," specifically Articles 3 and 17 [2]. - Key executives, including the chairman and general manager, the financial director, and the board secretary, were held primarily responsible for the violations [2]. - The Hubei Securities Regulatory Bureau decided to issue a warning letter and record it in the securities and futures market integrity file [2]. Group 3: Company Response - The company and responsible personnel acknowledged the warning and committed to learning from the issues raised, enhancing compliance with relevant laws and regulations, and improving the quality of information disclosure [2].

星标 ★ IPO日报 精彩文章第一时间推送 5月28日晚间，老牌药企广东嘉应制药股份有限公司（002198.SZ，下称"嘉应制药"）发布公告，公司于年5月28日收到证监会《立案告知书》， 因涉嫌信息披露违法违规被正式立案。 公司2025年4月26日发布的《内部控制自我评价报告》显示，众华会计师事务所对其出具了带强调事项段的无保留意见。 具体来看，2024年9月至2025年1月，全资子公司嘉应湖南向关联方湖南药聚能医药有限公司（实控人为董事长李能）累计转出资金1.7亿元，另向 非关联方转资6500万元。 为掩盖痕迹，资金采用"月初转出、月末归还"操作，使各月末账面余额归零，规避审计核查。 该行为未经董事会审批及披露，直至2025年1月23 日才全部归还。 制图：佘诗婕 截至5月29日收盘，公司股价大跌7.46%，市值单日蒸发超2亿元。5月30日，继续小跌0.48%。 公开信息显示，嘉应制药成立于2003年3月，是集研发、生产、销售为一体的中成药制药企业，于2007年12月在深交所挂牌上市。 业绩方面，截至2024年12月31日，公司实现营收3.76亿元，同比下降29.46%；归母净利润为2061万元，同比下降3 ...

Core Points - The company is preparing for the 2024 Annual General Meeting (AGM) scheduled for June 20, 2025, to discuss various proposals including the annual financial report and related transactions [3][4][28] - The company emphasizes the importance of maintaining shareholder rights and orderly conduct during the AGM, with specific guidelines for participation and voting [2][4][5] Group 1: Meeting Procedures - The AGM will be chaired by the company's board chairman, and a secretary will be appointed to manage the meeting procedures [3][4] - Shareholders are required to register their attendance to participate in voting and discussions, with specific rules regarding the validity of votes [2][5] - Legal representatives will be present to witness the meeting and provide legal opinions on the proceedings [2][5] Group 2: Proposals for Discussion - The agenda includes the review of the 2024 Board of Directors' work report, which outlines the company's strategic adjustments and innovations [4][5] - The company plans to discuss the 2024 financial statements, which have been audited and received a standard unqualified opinion from the auditing firm [28] - Proposals will also cover the annual profit distribution plan and the expected amounts for related party transactions for 2024 [20][28] Group 3: Corporate Governance - The company has established a governance structure that includes a board of directors, supervisory board, and various committees to ensure compliance and effective decision-making [6][9] - The board has been active in reviewing and approving significant operational and financial decisions, with a focus on risk management and compliance [7][9] - The company has implemented a comprehensive internal control system to monitor and manage risks effectively [7][26] Group 4: Financial Performance - The company reported its financial results for 2023, highlighting compliance with accounting standards and regulations [19][26] - The financial reports indicate a commitment to transparency and accuracy in financial disclosures, with regular audits conducted [14][26] - The company has outlined its plans for future financial management, including the use of raised funds and investment strategies [20][24]

Regulatory Developments - The Financial Regulatory Bureau issued a draft management method for information disclosure of asset management products, aiming to enhance transparency throughout the product lifecycle, ensuring clear understanding of sales, risks, and returns [1] Insurance Industry Trends - The expected reduction in the predetermined interest rate for life insurance may occur as early as the third quarter, following recent decreases in the loan market quotation rate (LPR) and bank deposit rates [2] - The third batch of long-term investment pilot institutions for insurance funds is being approved, including several small and medium-sized insurance companies, marking a new breakthrough in the number and type of participating institutions [3] Investment Activities - Insurance funds accelerated their equity market investments in Q1 2025, increasing stock investments by approximately 390 billion yuan, the largest quarterly increase in recent years, with a stock holding ratio rising to 8.37% [4] - A new equity investment fund, the Ping An Silver Age Equity Investment Fund, was established in Beijing with a capital contribution of 6 billion yuan, focusing on private equity investments and asset management [7] Corporate Actions - Ancheng Insurance announced the unconditional transfer of 18.77% of its shares to Chongqing Development Investment Co., Ltd., with the process of notifying shareholders completed [6] - Ping An Life appointed Shi Weiyu as the new general manager, aiming to enhance corporate governance and drive high-quality development, with the life and health insurance business showing a 5% increase in operating profit year-on-year and a 34.9% increase in new business value [8] Executive Changes - Sheneng Property Insurance has approved two new vice presidents, completing its core management structure with one general manager and four vice presidents, achieving nearly 100 million yuan in net profit in Q1 [9]

一周前，嘉应制药任职10个月的财务总监史俊平辞职。 嘉应制药主要从事中成药的研发、生产和销售，2007年12月登陆A股市场。上市以来，公司经营业绩整 体上不理想。2023年、2024年，公司营收净利双降，今年一季度，公司实现的归属母公司股东的净利润 （以下简称"归母净利润"）大增近2倍，但也只有1540万元。 长江商报消息 ●长江商报记者 沈右荣 老牌医药企业嘉应制药（002198.SZ）被立案调查了。 5月28日晚间，嘉应制药公告，当日，公司收到中国证监会的《立案告知书》，因公司涉嫌信息披露违 法违规，证监会决定对公司立案。对于具体所涉何事，嘉应制药在公告中没有提及。 Wind数据显示，上市18年来，嘉应制药累计盈利仅2.75亿元，累计仅进行5次现金分红，累计分红额不 到9000万元。 2024年，嘉应制药研发费用仅为675.72万元，销售费用1.37亿元。 嘉应制药靠什么突围？ 信披违规被立案调查 2020年8月，嘉应制药股东承诺12个月内增持不低于5%的股份，在延长12个月后，也仅增持0.16%的股 份，被广东证监局出具警示函，责令整改。当月，控股股东涉及表决权委托事宜，但未并告知嘉应制 药，未予以披露 ...

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission, leading to a significant drop in its stock price following the announcement of the investigation [1][2]. Group 1: Company Background - Jiaying Pharmaceutical is an established pharmaceutical company known for its research, production, and sales of traditional Chinese medicine, with key products including throat and cold medications [3]. - The company experienced a major shareholder restructuring in 2024 when Hunan Yantianhe Pharmacy acquired 7% of Jiaying's shares for a total of 355 million yuan [1]. Group 2: Recent Developments - The company faced regulatory scrutiny after its independent director, Li Shanwei, was found to have violated disclosure regulations by selling shares during a sensitive period without proper notice [2]. - Jiaying disclosed that it had engaged in non-compliant related party transactions, with a total of approximately 235 million yuan transferred to related parties, including 170 million yuan to a subsidiary of Yantianhe [2][3]. - In the fourth quarter of 2024, Jiaying reported a revenue decline of 25.3%, with total annual revenue falling to 376 million yuan, a year-on-year decrease of 29.46% [3].

新疆天顺供应链股份有限公司 年报信息披露重大差错责任追究制度 第一章 总则 第一条 为了进一步提高公司的规范运作水平，增强信息披露的真实性、准 确性、完整性和及时性，提高年报信息披露的质量和透明度，根据《中华人民共 和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国证券法》 （以下简称"《证 券法》"）、 《上市公司信息披露管理办法》 《深圳证券交易所股票上市规则》 《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关法 律、法规，结合公司实际情况，特制定本制度。 第二条 本制度所指责任追究制度是指年报信息披露工作中有关人员不履行 或者不正确履行职责、义务或其他个人原因，导致年报披露信息出现重大会计差 错、其他年报信息披露存在重大错误或重大遗漏、业绩预告或业绩快报存在重大 差异等情形，对公司造成重大经济损失或造成不良社会影响时的追究与处理制度。 第三条 本制度适用于公司董事、高级管理人员以及其他与年报信息披露工 作有关的其他人员。 第四条 实行责任追究制度，应遵循以下原则： 第五条 公司证券部在董事会秘书领导下负责收集、汇总与追究责任有关的 资料，按制度规定提出相关处理方 ...